"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves niraparib (Zejula) for patients with Ovarian, Fallopian tube, or Peritoneal Cancer

31 Oct 2019 1:57 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved niraparib (Zejula; Tesaro), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software